ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0643

Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection

Carlos González1, Luis Menchén1, Indalecio Monteagudo1, Ofelia Baniandrés2, Juan Carlos Nieto Gonzalez1, Ignacio Marín-Jiménez1, Ana Herranz-Alonso1, Carmen Lobo-Rodríguez1, Amparo López-Esteban1, Ana López1, Arantza Ais-Larisgoitia1, Esther Chamorro de Vega1, Paloma Morales de los Ríos1, Maria Jesús Lizcano1, Jose Maria Alvaro-Gracia1 and Sonia García de San-José1, 1CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain

Meeting: ACR Convergence 2020

Keywords: Biologicals, COVID-19, Managed Care

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Session Title: Infection-related Rheumatic Disease Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To analyze the risk of admission for COVID19 infection and outcome of patients treated with b/tsDMARD  from our center, to compare with all patients admitted for COVID-19 infection.

Methods: Records of the b/tsDMARD patients  admitted for COVID-19 infection between March 8 and June 8, 2020 were analyzed retrospectively. Age, gender, and outcome of all patients admitted to our hospital for COVID19 infection on the same dates were collected. Chi-square, Student’s t and Man-Whitney U tests were used when appropriate.

Results: 1,668 patients with IMID treated with b/tsDMARD were included. Median age 53.0 years (range 17-91), 52.4% women. Diagnoses and DMARD distribution are shown in tables 1 and 2. 21/1668 (1.3%; 4.2/100 patient-years) were admitted for severe COVID19 infection. Mortality ratio: 4/21 (19.0%). Median age of the admitted patients was higher: 61.0y (SD 14.7) vs 53.0y (SD 15.0); p < 0.006. Median age of deceased patients was also higher 69.5y (SD 20.3) vs 53.0y (SD 15.0); p: NS. Female gender had a worse prognosis trend: 52.4% of all group, 61.9% of those hospitalized, 75.0% of those who died. Females had a higher median age than men: 55.0y (SD 14.9) vs. 50.0y (SD 14.9); p < 0.001.

When comparing patients treated with DMARD admitted for COVID19 infection with all patients hospitalized for the same reason (2,684 patients), no differences were found neither in age (61.0y [SD 14.7] vs 60.0y [SD 19.0]; NS) nor gender (female: 61.9% vs 50.2%; NS). Mortality rate was not different: 4/21 (21.0%) vs 551/2684 (20.5%); p: NS, but patients treated with b/tsDMARD died at a younger age: 69.5y (SD 20.3) vs 81.5 (SD 11.3); p: NS.

Rheumatoid arthritis patients were admitted more frequently: (9/392 (2.3%) vs 12/1276 (0.9%); p < 0.035. And were older: median 62y (SD 13.5) vs 50.0y (SD 14.4); p < 0.001.

Patients treated with anti-TNF suffered less admissions: 6/1055 (0.6%) vs 15/613 (2.4%); p< 0.001 and were younger: median 51.0y (SD 15.0) vs 55.0y (SD 14.7); p < 0.001. Anti-TNF were less used in patients with rheumatoid arthritis 188/392 (48.0%) vs 867/1276 (67.9%); p< 0.001. Table 1:

Disease

N (%)

Admitted

deaths

Rheumatoid arthritis

Spondylarthritis

Psoriatic arthritis

JIA

CTD

Vasculitis

IBD

Psoriasis

others

392 (23.5%)

277 (16.6%)

124 (7.4%)

30 (1.8%)

31 (1.9%)

20 (1.2%)

582 (34.9%)

202 (12.1%)

10 (0.6%)

9/392 (2.3%)

3/277 (1.1%)

1/124 (0.8%)

0/30 (0.0%)

1/31 (3.2%)

0/20 (0.0%)

4/578 (0.7%)

3/202 (1.5%)

0/10 (0.0%)

1

1

0

0

1

0

1

0

0

TOTAL

1,668 (100%)

21/1668 (1.3%)

4/21 (19.0%)

Table 2:

Treatment

N (%)

Admitted

deaths

Anti-TNF

Anti-CD20

Anti-IL6

CTLA4-Ig

Anti-IL17

Anti-IL12/23

Anti-integrin

JAK inhibitor

PDE4 inhibitor

Anti-IL23

1055 (63.2%)

79 (4.7%)

96 (5.8%)

44 (2.6%)

92 (5.5%)

143 (8.6%)

79 (4.7%)

34 (2.0%)

32 (1.9%)

14 (0.8%)

6/1055 (0.6%)

3/79 (3.8%)

3/96 (3.1%)

3/44 (6.8%)

3/92 (3.3%)

1/143 (0.7%)

0/79 (0.0%)

1/34 (2.9%)

1/32 (3.1%)

0/14 (0.0%)

2

1

0

1

0

0

0

0

0

0

TOTAL

1,668 (100%)

21/1668 (1.3%)

4/21 (19.0%)

Conclusion: It is  reasonable that patients with inflammatory diseases treated with b/tsDMARD continue their treatment during the COVID19 epidemic. The different rates of hospitalization based on the diagnosis or DMARD may be due to comorbidity, confounding by indication and other bias. The study is not powerful enough to study these confounders.


Disclosure: C. González, Abbvie, 8, Celgene, 8, Gilead, 5, 8, Janssen, 5, 8, novartis, 5, 8, Pfizer, 8, Roche, 8, Merck, 5; L. Menchén, Abbvie, 2, 5, 8, Janssen, 2, 5, 8, Takeda, 2, 5, 8, Merck, 2, 5, 8, Medtronic, 5, Tillots, 5, 8, Pfizer, 5, 8; I. Monteagudo, None; O. Baniandrés, None; J. Nieto Gonzalez, None; I. Marín-Jiménez, Abbvie, 5, 8, Chiesi, 5, 8, FAES, 5, 8, Otsuka, 5, 8, Merck, 5, 8, Janssen, 5, 8, Hospira, 5, 8, Gebro, 5, 8; A. Herranz-Alonso, None; C. Lobo-Rodríguez, None; A. López-Esteban, None; A. López, None; A. Ais-Larisgoitia, None; E. Chamorro de Vega, None; P. Morales de los Ríos, None; M. Lizcano, None; J. Alvaro-Gracia, Abbvie, 2, 5, 8, lilly, 2, 5, 8, Merck, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, UCB, 5, 8, Sanofi, 5, 8; S. García de San-José, None.

To cite this abstract in AMA style:

González C, Menchén L, Monteagudo I, Baniandrés O, Nieto Gonzalez J, Marín-Jiménez I, Herranz-Alonso A, Lobo-Rodríguez C, López-Esteban A, López A, Ais-Larisgoitia A, Chamorro de Vega E, Morales de los Ríos P, Lizcano M, Alvaro-Gracia J, García de San-José S. Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/use-of-biologic-treatment-and-risk-to-be-admitted-for-covid-19-infection/. Accessed June 29, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-biologic-treatment-and-risk-to-be-admitted-for-covid-19-infection/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies